Here's a rephrased version of the content to make it plagiarism-free and unique:
As per sources familiar with the matter, the Biden administration is on the brink of reclassifying marijuana from a Schedule I drug to a Schedule III drug, marking a pivotal moment in the evolution of U.S. drug policy.
In contrast to Schedule I, Schedule III drugs are recognized for their medicinal properties and lower potential for abuse. Sources have informed NBC News that the Drug Enforcement Administration is likely to approve a recommendation from the Department of Health and Human Services, paving the way for medical cannabis research to commence.
This development follows President Biden's 2022 directive to the HHS to reassess the classification of marijuana. The proposed reclassification acknowledges marijuana's lower addiction potential compared to its current classification. However, it does not legalize recreational marijuana at the federal level, leaving its legality subject to state laws.
Bradley Cobb, the founder and CEO of Sunburn Cannabis, a medical marijuana treatment center in Florida, shared the unique backstory behind the company's name, which stems from his father's involvement in cannabis smuggling. Cobb expressed mixed feelings about the decision, viewing it as a validation of his belief that marijuana should be treated like any other substance, and as an opportunity to destigmatize it.
The reclassification is viewed as a significant step towards reforming marijuana laws, as public opinion has shifted notably in favor of legalization. Melba Pearson, director of prosecution projects at Florida International University, noted that the reclassification has sparked discussions about restorative justice, especially regarding individuals with cannabis convictions.
Despite opposition, experts believe the move could garner political support, particularly among young and Black voters. In Florida, where recreational marijuana is still illegal, voters will decide its fate through ballot initiative Amendment 3 in November.